See the immunogenicity in infants and toddlers
Most infants and toddlers who completed the 4-dose series had a protective immune response with MENVEO1
- The primary endpoint for MENVEO (adequacy of immune response) was met following the full 4-dose series, given at 2, 4, 6, and 12 months of age*
- *Prespecified criteria for adequacy of immune response were met (lower limit of the 95% CI ≥80% for serogroup A and ≥85% for serogroups C, W, and Y).1
Geometric mean titers (GMTs) are a measure of the level of immune response to a vaccine in a specific study group. Infants and toddlers vaccinated with MENVEO were found to have circulating bactericidal antibodies to MenACWY following the full 4-dose series.
CI=confidence interval; MenACWY=meningococcal serogroups A, C, W, Y; MMRV=measles, mumps, rubella, varicella; hSBA=human serum bactericidal assay.
- †hSBA GMTs at 1-month post-dose 3 and 1-month post-dose 4 of MENVEO with routine infant/toddler vaccines.1
Randomized, controlled, multicenter study of infants initiating vaccination at 2 months of age with either MENVEO concomitantly with routine infant vaccines (diphtheria toxoid, tetanus toxoid, and acellular pertussis, inactivated poliovirus types 1, 2, and 3, hepatitis B, Haemophilus influenzae type b, pentavalent rotavirus, and 7-valent pneumococcal conjugate [PCV7]) or routine infant vaccines alone. Toddlers received the fourth dose of MENVEO concomitantly with PCV7, MMRV (measles, mumps, rubella, varicella), and inactivated hepatitis A vaccines.1